Hormonal Therapy in Metastatic Prostatic Cancer
The concept of hormonal therapy for prostatic cancer was introduced in 1941 by Huggins and Hodges with the prospect of curing even the most advanced of cases. They reasoned that since normal prostatic epithelium is androgen dependent, prostatic cancer should be similarly dependent. They and others then demonstrated that human prostatic cancer could be made to regress by the administration of pharmacologic doses of estrogens or by castration (Huggins et al. 1941; Spirnak and Resnick 1983). However, after a decade of enthusiastic and optimistic use of these forms of androgen ablation in all stages of prostatic cancer, it became apparent that hormonal therapy was not to be the panacea initially envisaged. Clinical studies conducted from 1942 to 1983 failed to define clearly the indications for this treatment except to demonstrate that hormonal therapy could not cure prostatic cancer. Studies by Vest and Frazier (1946), Nesbit and Plumb (1946), and Nesbit and Baum (1950) all suggested that hormonal therapy prolonged survival of patients with metastatic disease. However, the Veterans Administration Cooperative Urological Research Group (VACURG) (1967) failed to demonstrate any survival benefit of early hormonal therapy in advanced disease. Lepor et al. (1982) compared the survival of patients with metastatic disease treated immediately prior to the introduction of hormonal therapy with that in patients treated immediately after.
KeywordsProstatic Cancer Hormonal Therapy Advanced Prostatic Cancer Metastatic Prostatic Cancer Luteinizing Hormone Release Hormone
Unable to display preview. Download preview PDF.
- Beland J, Elhilali M (1986) A prospective randomized trial of total androgen ablation in metastatic prostatic cancer (abstr). Proceedings of the Second International Conference on Prostate Cancer. ParisGoogle Scholar
- Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297Google Scholar
- Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–223Google Scholar
- Labrie F, Dupont A, Belanger A et al. (1985) Antiandrogens and LHRH agonists in the treatment of prostatic cancer. Medicine/Science 1: 435Google Scholar
- Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320Google Scholar
- Schroder FH, Klijn JG, de Jong FH (1986) Metastatic cancer of the prostate managed by Buserelin acetate versus Buserelin acetate plus cyproterone acetate. Proceedings of the Annual Meeting of the American Urological Association, New York. J Urol 135: 202AGoogle Scholar
- Tolis G, Menta A, Kinch R, Comaru-Schally AM, Schally AV (1980) Suppression of sex steroids by an LH-Rh analogue in man. Clin Res 28: 676AGoogle Scholar
- Trachtenberg J, Zadra J (1986) Total androgen ablation therapy in the treatment of advanced prostatic cancer. Proceedings of the Annual Meeting of the American Urological Association, New York. J Urol 135: 201AGoogle Scholar
- Veterans Administration Cooperative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017Google Scholar